Folate receptor: a potential target in ovarian cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33155448" target="_blank" >RIV/61989592:15110/15:33155448 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1515/pterid-2014-0013" target="_blank" >http://dx.doi.org/10.1515/pterid-2014-0013</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1515/pterid-2014-0013" target="_blank" >10.1515/pterid-2014-0013</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Folate receptor: a potential target in ovarian cancer
Popis výsledku v původním jazyce
Ovarian cancer is the most frequent cause of gynecological cancer-related death. Unfortunately, many patients are diagnosed at an advanced stage and have a poor prognosis. The standard treatment for advanced disease involves maximal cytoreductive surgeryand chemotherapy based on platinum compounds and taxanes. Patients presenting at an advanced stage have a higher risk of recurrence. The development of drug resistance currently represents a major obstacle in the systematic treatment and, therefore, thediscovery of new anticancer agents and approaches should improve the poor prognosis of these patients. Folate receptor a is overexpressed in epithelial ovarian cancer (EOC), but has limited expression in nonmalignant human tissues. The degree of folatereceptor expression corresponds with the stage and grade of the disease. Because of this, folate receptor a seems to be a potential therapeutic target for the treatment of ovarian cancer. Currently, several approaches have been studied to
Název v anglickém jazyce
Folate receptor: a potential target in ovarian cancer
Popis výsledku anglicky
Ovarian cancer is the most frequent cause of gynecological cancer-related death. Unfortunately, many patients are diagnosed at an advanced stage and have a poor prognosis. The standard treatment for advanced disease involves maximal cytoreductive surgeryand chemotherapy based on platinum compounds and taxanes. Patients presenting at an advanced stage have a higher risk of recurrence. The development of drug resistance currently represents a major obstacle in the systematic treatment and, therefore, thediscovery of new anticancer agents and approaches should improve the poor prognosis of these patients. Folate receptor a is overexpressed in epithelial ovarian cancer (EOC), but has limited expression in nonmalignant human tissues. The degree of folatereceptor expression corresponds with the stage and grade of the disease. Because of this, folate receptor a seems to be a potential therapeutic target for the treatment of ovarian cancer. Currently, several approaches have been studied to
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/LO1304" target="_blank" >LO1304: Podpora udržitelnosti Ústavu molekulární a translační medicíny</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Pteridines
ISSN
0933-4807
e-ISSN
—
Svazek periodika
26
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
12
Strana od-do
1-12
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—